Second Quarter 2010 Results
Revenue for the second quarter of 2010 increased 23.3% to $40.9 million, from $33.2 million in the same 2009 period. Revenue growth is primarily attributable to price increases ranging from 0.1% to 433.5% across the Company's plasma-based product portfolio. Rising pricing reflects continued supply shortage in China's plasma industry. The Company generally expects pricing to remain stable during the balance of the year, while management continues to monitor the impact of China's health care reform efforts on procurement and pricing for products listed within China's National Medical Insurance Catalog. Among the Company's product groups, while Human Albumin pricing remained flat relative to the second quarter of 2009, it remained the largest revenue contributor at 46.4% of total sales. Human Immunoglobulin for Intravenous Injection, the Company's most in-demand product group and second largest revenue contributor at 39.3% of total sales, experienced average year-over-year price increases of 26.9% in second quarter 2010. Human Hepatitis B Immunoglobulin experienced the sharpest average price increase among the Company's product categories, up 433.5% compared to the prior year period, and contributed 6.9% of total revenues in second quarter 2010.
Gross profit for the second quarter of 2010 was $31.8 million, up 32.6%,
from $24.0 million in the second quarter of 2009. Gross profit margin expanded
to 77.9% from 72.4% in the same period a year ago and 74.9% in the first
quarter of 2010. The gross profit margin expansion was primarily attributable
to the increase in the average selling price, as well as s
|SOURCE China Biologic Products, Inc.|
Copyright©2010 PR Newswire.
All rights reserved